Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.

Cancer EORTC QLQ-C30 Group-level change Health-related quality of life (HRQoL) Minimally important difference (MID) Patient-reported outcomes (PRO)

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
07 2023
Historique:
received: 15 02 2023
revised: 27 04 2023
accepted: 27 04 2023
medline: 19 6 2023
pubmed: 1 6 2023
entrez: 31 5 2023
Statut: ppublish

Résumé

Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale, direction of change, cancer type and estimation method has raised doubt about a single global standard. This paper identifies MID patterns for interpreting group-level change in EORTC QLQ-C30 scores across nine cancer types. Data were obtained from 21 published EORTC Phase III trials that enroled 13,015 patients across nine cancer types (brain, colorectal, advanced breast, head/neck, lung, mesothelioma, melanoma, ovarian, and prostate). Anchor-based MIDs for within-group change and between-group differences in change over time were obtained via mean change method and linear regression, respectively. Separate MIDs were estimated for improvements and deteriorations. Distribution-based estimates were derived and compared with anchor-based MIDs. Anchor-based MIDs mostly ranged from 5 to 10 points. Differences in MIDs for improvement vs deterioration, for both within-group and between-group, were mostly within a 2-points range. Larger differences between within-group and between-group MIDs were observed for several scales in ovarian, lung and head/neck cancer. Most anchor-based MIDs ranged between 0.3 SD and 0.5 SD distribution-based estimates. Our results reinforce recent claims that no single MID can be applied to all EORTC QLQ-C30 scales and disease settings. MIDs varied by scale, improvement/deterioration, within/between comparisons and by cancer type. Researchers applying commonly used rules of thumb must be aware of the risk of dismissing changes that are clinically meaningful or underpowering analyses when smaller MIDs apply.

Identifiants

pubmed: 37257278
pii: S0959-8049(23)00228-9
doi: 10.1016/j.ejca.2023.04.027
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-182

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jammbe Z Musoro (JZ)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Electronic address: jammbe.musoro@eortc.org.

Corneel Coens (C)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Mirjam A G Sprangers (MAG)

Amsterdam UMC Location University of Amsterdam, Medical Psychology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.

Yvonne Brandberg (Y)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Mogens Groenvold (M)

Department of Public Health, University of Copenhagen, and Bispebjerg Hospital, Copenhagen, Denmark.

Hans-Henning Flechtner (HH)

Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, Germany.

Kim Cocks (K)

Adelphi Values, Bollington, Cheshire, UK.

Galina Velikova (G)

Leeds Institute of Medical Research at St James's, University of Leeds, St James's University Hospital, Leeds, UK; Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK.

Linda Dirven (L)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.

Elfriede Greimel (E)

Medical University Graz, Graz, Austria.

Susanne Singer (S)

Institute of Medical Biostatistics, Epidemiology and Informatics, Division of Epidemiology and Health Services Research, University Medical Centre Mainz, Germany; University Cancer Centre Mainz, Germany.

Katarzyna Pogoda (K)

Departmenf of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Eva M Gamper (EM)

Innsbruck Institute of Patient-centered Outcome Research (IIPCOR), Innsbruck, Austria.

Samantha C Sodergren (SC)

School of Health Sciences, University of Southampton, Southampton, UK.

Alexander Eggermont (A)

Princess Máxima Center, Utrecht and University Medical Center Utrecht, The Netherlands; Comprehensive Cancer Center Munich, Technical University Munich & Ludwig Maximiliaan University, Munich, Germany.

Michael Koller (M)

Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.

Jaap C Reijneveld (JC)

Amsterdam University Medical Centers, location VU University Medical Center, Department of Neurology Brain Tumor Center, Amsterdam, The Netherlands.

Martin J B Taphoorn (MJB)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.

Madeleine T King (MT)

University of Sydney, Faculty of Science, School of Psychology, Sydney, NSW, Australia.

Andrew Bottomley (A)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH